Formula I Compounds for Parasitic Disease Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for leishmaniasis, Chagas disease, and Human African Trypanosomiasis are limited by efficacy, safety concerns, drug resistance, stability issues, and lack of oral dosing options, with geographical variations in treatment effectiveness and significant side effects.
Innovation Solution
Development of specific compounds, such as those represented by Formula (I) and its salts, which are used in pharmaceutical compositions for the treatment and prevention of these parasitic diseases, offering potential as new oral agents with improved efficacy and safety profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for leishmaniasis, Chagas disease, and Human African Trypanosomiasis are used, then parasitic diseases can be treated, but efficacy varies geographically and drug resistance develops
Solution Approach 1:
The patent employs parameter changes by modifying chemical structures (Formula I compounds with varying R groups, linkers L1-L3, and substituents) to optimize pharmacological properties including efficacy, stability, and oral bioavailability. This systematic variation of molecular parameters enables development of compounds with improved and consistent therapeutic effects across different geographical regions and parasite strains
2Reliability
If current treatments are administered, then parasitic infections can be addressed, but serious side effects and safety concerns arise
Solution Approach 1:
The patent applies local quality by designing compounds with specific functional groups and substituents (R1-R15, Ar, Cy, Het) that target parasitic pathways selectively. The molecular structure is optimized to enhance interaction with parasite-specific targets while minimizing off-target effects on human cells, thereby improving the therapeutic index and reducing side effects
Solution Approach 2:
The patent converts the harmful effect of drug resistance into a benefit by designing compounds with novel mechanisms of action that bypass resistant parasite strains. The chemical diversity in Formula I compounds allows selection of agents effective against multidrug-resistant parasites, turning the challenge of resistance into an opportunity for developing superior therapies
3Ease of operation
If current treatments are used, then disease management is possible, but lack of oral dosing options limits patient compliance
Solution Approach 1:
The patent substitutes parenteral administration (injections) with oral administration by designing compounds with appropriate pharmacokinetic properties. The Formula I compounds are structured to achieve sufficient oral bioavailability, allowing patients to take medication orally rather than requiring invasive injections, thereby improving convenience and compliance
4Reliability
If current treatments are administered, then parasitic diseases can be managed, but stability issues affect drug performance
Solution Approach 1:
The patent employs composite material principles by combining multiple functional groups and structural elements in Formula I compounds. The molecules integrate core heterocyclic structures with various substituents (Ar, Cy, Het, R groups) that collectively provide both therapeutic activity and enhanced stability. This composite molecular architecture improves resistance to degradation while maintaining pharmacological efficacy
Data Source
AI summary
A compound of Formula (I), or a salt thereof, compositions comprising the compound, processes for its preparation and its use in therapy, for example in the treatment of parasitic diseases such as Chagas disease, Human African Trypanosomiasis (HAT), Animal African trypanosomiasis (AAT) and leishmaniasis, particularly visceral leishmaniasis (VL).